Clinical efficacy and safety of intracoronary verapamil during percutaneous coronary intervention in patients with acute coronary syndromes / 中华老年医学杂志

ABSTRACT

Objective To examine the clinical efficacy and safety of intracoronary verapamil during percutaneous coronary intervention(PCI) in patients with acute coronary syndromes (ACS).Methods Totally 98 patients with ACS undergoing PCI were randomly assigned to two groupsverapamil group (immediately intracoronary verapamil 200 μg/2 ml heparinised saline,n=48) and intracoronary saline control group (immediately intracoronary 2 ml heparinised saline,n=50) after deploying stent.The follow up time was 3 months.Thrombolysis in myocardial infarction (TIMI)flow grade (TFG), corrected TIMI frame count (CTFC),TIMI myocardial perfusion grade (TMPG), myocardial blush grade (MBG) were assessed pre- and post-PCI and after drug administration.Echocardiography were performed one week after PCI. Incidence of major adverse cardiac events in hospital and 3 months follow-up were compared between the two groups. Results The differences in values of CTFC,TFG,TMPG,MBG after PCI were not found between two groups (P＞0.05). However,after intracoronary drug administration,verapamil group was superior to control group in terms of CTFC (t=6.47,P＜0.01),TFG (x2=5.17,P＜0.01),TMPG(x28.25,P＜0.01)and MBG(x2=2.12,P＜0.05).After correcting the influencing factors,only CTFC was still improved in verapamil group than in control group (x2 =2.36,P＜0.05).There were no significant differences between the two groups in TFG(x2 =0.58,P＞0.05)and MBG(x2 =0.91,P＞0.05) and TMPG (x2 =0.68,P＞0.05).Echocardiographic results after PCI were similar between two groups (x2 =0.65,P＞0.05).There was no difference in major adverse cardiac events between two groups (x2 =0.71,P ＞ 0.05 ). Conclusions Application of intracoronary verapamil after deploying stent is effective,safety and worthy of popularization in view of improving post procedural coronary flow in patients with ACS.